MBRX

Moleculin Biotech, Inc. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website moleculin.com
Employees(FY) 15
ISIN US60855D3098

Performance

-32.11%

-36.14%

-32.11%

-58.04%

-87.03%

YTD

-83.77%

Profile

Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066 that is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It is also developing WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company was incorporated in 2015 and is headquartered in Houston, Texas.

Advanced Technical Analysis

Technical Analysis of MBRX 2024-12-20

The stock indicators reflect a bearish sentiment, with the Moving Average Score at 10, Oscillators Score at 36, and a Technical Score of 23, indicating overall weakness in price momentum and suggesting caution for potential investors. The low scores across all categories highlight a lack of bullish signals in the current market environment.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of MBRX

Stock Rank

Recent News & Updates

2024-12-10 19:00
Moleculin Announces Online Publication of Preclinical Data Demonstrating Significant Activity of Annamycin in Venetoclax Resistant AML Model(Prnewswire)
2024-11-17 19:15
New Findings Show Moleculin's Annamycin Overcomes Resistance to Venetoclax in AML(Prnewswire)
2024-11-13 19:15
Moleculin Accelerates Planned Unblinded Data Readout for MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial to H2 2025(Prnewswire)
2024-11-12 09:59
Moleculin Biotech Reports Financial Highlights and Future Plans(Yahoo Finance)
2024-11-11 19:00
Moleculin Receives Institutional Review Board Approval for MIRACLE Phase 3 Pivotal Trial of Annamycin in Combination with Cytarabine for the Treatment of R/R Acute Myeloid Leukemia (AML)(Prnewswire)
2024-11-11 10:19
Q3 2024 Moleculin Biotech Inc Earnings Call(Yahoo Finance)
2024-11-10 18:05
Moleculin Reports Third Quarter 2024 Financial Results and Provides Corporate Update(Prnewswire)
2024-11-04 20:00
Moleculin to Report Third Quarter 2024 Financial Results on November 8, 2024 and Host Conference Call and Webcast(Prnewswire)
2024-11-03 19:30
Moleculin Appoints Leading Expert in Pancreatic Cancer to its Scientific Advisory Board to Support Development of Annamycin(Prnewswire)
2024-10-17 20:57
Moleculin Biotech Highlights Annamycins AML Treatment Potential(Yahoo Finance)
2024-10-16 20:40
Transcript from Moleculin's Recent Virtual Acute Myeloid Leukemia KOL Event Now Available(Prnewswire)
2024-10-09 05:02
Moleculin Biotech Inc (MBRX) Q2 2024 Earnings Call Highlights: Pivotal Phase 3 Trial for ...(Yahoo Finance)
2024-10-06 20:30
Moleculin to Host Virtual Acute Myeloid Leukemia KOL Event on October 14, 2024(Prnewswire)
2024-10-03 21:00
Moleculin to Present at Two Upcoming Investor Conferences(Prnewswire)
2024-09-22 20:00
Moleculin Announces Positive In Vivo Efficacy Data of Annamycin in Orthotopic and Experimental Lung Metastatic Models of Sarcoma(Prnewswire)
2024-09-15 20:30
Moleculin Participates in Virtual Investor 'What this Means' Segment(Prnewswire)
2024-09-08 20:15
Moleculin Announces First Patients Treated in Phase 2 Clinical Trial of STAT3 Inhibitor in Combination with Radiation for the Treatment of Glioblastoma(Prnewswire)
2024-09-02 21:15
Moleculin to Present at the H.C. Wainwright 26th Annual Global Investment Conference(Prnewswire)
2024-08-25 20:30
Moleculin to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar(Prnewswire)
2024-08-19 04:05
Moleculin Announces Closing of up to $16.5 Million Public Offering(Prnewswire)
2024-08-15 20:00
Moleculin Announces Pricing of up to $16.5 Million Public Offering(Prnewswire)
2024-08-13 20:05
Moleculin Reports Second Quarter 2024 Financial Results and Provides Corporate Update(Prnewswire)
2024-08-04 21:05
Moleculin to Host Webcast Presentation to Discuss Recently Announced Plans for MIRACLE Phase 3 Pivotal Trial Tuesday, August 6, 2024 at 8:30 AM ET(Prnewswire)
2024-07-31 20:30
Moleculin Announces Plans for MIRACLE Phase 3 Pivotal Trial(Prnewswire)
2024-07-09 20:30
Moleculin Completes End of Phase 2 Meeting with FDA for Annamycin in AML(Prnewswire)
2024-06-16 20:00
Final Participating Company Line-Up Announced for the Virtual Investor Pitch Conference Hosted by JTC Team Being Held June 17 - 18, 2024(Accesswire)
2024-06-13 20:00
Moleculin Announces Additional Positive Preliminary Interim Data from AML Clinical Trial(Prnewswire)
2024-06-11 21:00
Moleculin to Present at the Virtual Investor Pitch Conference(Prnewswire)
2024-06-09 20:00
JTC Team Announces Participating Company Line-Up for the Virtual Investor Pitch Conference on June 17-18, 2024(Accesswire)
2024-06-04 20:55
Moleculin to Participate in the Virtual Investor Lunch Break Series(Prnewswire)

Page 1 of 6

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.